Viking Therapeutics (VKTX) Interest & Investment Income (2014 - 2026)
Viking Therapeutics' (VKTX) quarterly Interest & Investment Income came in at $4.5 million in Q2 2026, down 49.68% year-over-year from $9.0 million in Q2 2025, and down 21.64% quarter-over-quarter from $5.8 million in Q1 2026.
Powered by 
Analysis
Viking Therapeutics (VKTX) Interest & Investment Income (2014 - 2026) Analysis & Trends
Viking Therapeutics has disclosed Interest & Investment Income across 13 years of filings, most recently posting $4.5 million for Q2 2026.
- In Q2 2026, Interest & Investment Income fell 49.68% year-over-year to $4.5 million; the TTM figure through Jun 2026 stood at $25.2 million (down 39.06% YoY), while the FY2025 annual figure was $33.7 million, down 17.67% from the prior year.
- Interest & Investment Income came in at $4.5 million for Q2 2026 at Viking Therapeutics, down from $5.8 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $11.8 million in Q2 2024 to a low of -$893000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $5.6 million, with a median of $5.3 million recorded in 2023.
- Year-over-year, Interest & Investment Income plunged 473.64% in 2022 and surged 1697.23% in 2023.
- Over 5 years, Interest & Investment Income stood at $732000.0 in 2022, then soared by 542.9% to $4.7 million in 2023, then surged by 130.43% to $10.8 million in 2024, then sank by 35.13% to $7.0 million in 2025, then tumbled by 35.39% to $4.5 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $4.5 million in Q2 2026, $5.8 million in Q1 2026, and $7.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 219.00 Mn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | -679.00 Mn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | 80.00 Mn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | - |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 120.60 Mn |
| 10 | Viking Therapeutics | 4.86 Bn | 4.86 Bn | - | 4.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.55 Mn |
| Mar 31, 2026 | 5.80 Mn |
| Dec 31, 2025 | 7.04 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Mar 31, 2025 | 9.86 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | 11.53 Mn |
| Jun 30, 2024 | 11.82 Mn |
| Mar 31, 2024 | 6.75 Mn |
| Dec 31, 2023 | 4.71 Mn |
| Sep 30, 2023 | 4.73 Mn |
| Jun 30, 2023 | 4.55 Mn |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 732,000.00 |
| Sep 30, 2022 | 450,000.00 |
| Jun 30, 2022 | 253,000.00 |
| Mar 31, 2022 | -893,000.00 |
| Dec 31, 2021 | 159,000.00 |
| Sep 30, 2021 | 125,000.00 |
API Access
Viking Therapeutics Interest & Investment Income API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=interest-and-investment-income&ticker=VKTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "interest-and-investment-income", "ticker": "VKTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=interest-and-investment-income&ticker=VKTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();